Evidence map›Paper›PMID 35924166›Full record

ArticleFrontiers in oncology2022

Loss of Frizzled 9 in Lung Cells Alters Epithelial Phenotype and Promotes Premalignant Lesion Development.

Kayla Sompel, Lori D Dwyer-Nield, Alex J Smith, Alamelu P Elango, Lauren A Vanderlinden, Katrina Kopf, Robert L Keith, Meredith A Tennis

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kayla SompelSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Lori D Dwyer-NieldSkaggs School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Alex J SmithSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Alamelu P ElangoSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Lauren A VanderlindenSchool of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Katrina KopfOffice of Academic Affairs, National Jewish Health, Denver, CO, United States.
Robert L KeithSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Meredith A TennisSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
University of Colorado Anschutz Medical Campus · USColorado School of Public Health · USNational Jewish Health · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Frizzled 9 loss and regulation in preventing the progression of pre-malignant lung lesionsR01CA214531 · NCI · UNIVERSITY OF COLORADO DENVER · PI TENNIS, MEREDITH A · 2017 to 2021
$1.8M
NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA214531
6 · The paper itself

Abstract

The transmembrane receptor Frizzled 9 (FZD9) is important for fetal neurologic and bone development through both canonical and non-canonical WNT/FZD signaling. In the adult lung, however, Fzd9 helps to maintain a normal epithelium by signaling through peroxisome proliferator activated receptor γ (PPARγ). The effect of FZD9 loss on normal lung epithelial cells and regulators of its expression in the lung are unknown. We knocked down FZD9 in human bronchial epithelial cell (HBEC) lines and found that downstream EMT targets and PPARγ activity are altered. We used a FZD9

Indexed as

EMTFrizzled 9lung cancerpremalignant lesionstransformed growth

Identifiers

PMID35924166
PMCPMC9343062
OpenAlexW4285803525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.